12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Maraviroc: Phase III final data

Final 48-week data from double-blind, U.S. and Canadian Phase III MOTIVATE-2 trial in 464 treatment-experienced patients showed that maraviroc plus optimized background therapy (OBT) decreased mean HIV-1 RNA from baseline by 1.72 log10 and 1.87 log10 when given once daily...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >